MY153610A - Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine - Google Patents

Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine

Info

Publication number
MY153610A
MY153610A MYPI2011000931A MYPI20110931A MY153610A MY 153610 A MY153610 A MY 153610A MY PI2011000931 A MYPI2011000931 A MY PI2011000931A MY PI20110931 A MYPI20110931 A MY PI20110931A MY 153610 A MY153610 A MY 153610A
Authority
MY
Malaysia
Prior art keywords
dose combination
fixed dose
aliskiren
amlodipine
minutes
Prior art date
Application number
MYPI2011000931A
Other languages
English (en)
Inventor
Valazza Stephen
Wagner Robert Frank
Vippagunta Sudha
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42040192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY153610(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY153610A publication Critical patent/MY153610A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2011000931A 2008-09-22 2009-09-22 Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine MY153610A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9894508P 2008-09-22 2008-09-22

Publications (1)

Publication Number Publication Date
MY153610A true MY153610A (en) 2015-02-27

Family

ID=42040192

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011000931A MY153610A (en) 2008-09-22 2009-09-22 Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine

Country Status (21)

Country Link
US (1) US8613949B2 (enExample)
EP (1) EP2328564A2 (enExample)
JP (2) JP2012503020A (enExample)
KR (1) KR20110060942A (enExample)
CN (1) CN102159195A (enExample)
AR (1) AR073384A1 (enExample)
AU (1) AU2009292908B2 (enExample)
BR (1) BRPI0919350A2 (enExample)
CA (1) CA2736257A1 (enExample)
CL (1) CL2011000594A1 (enExample)
CO (1) CO6351711A2 (enExample)
EC (1) ECSP11010999A (enExample)
IL (1) IL211571A0 (enExample)
JO (1) JO3239B1 (enExample)
MA (1) MA32719B1 (enExample)
MX (1) MX2011002988A (enExample)
MY (1) MY153610A (enExample)
PE (1) PE20110293A1 (enExample)
RU (2) RU2011115712A (enExample)
TW (1) TW201016217A (enExample)
WO (1) WO2010033954A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2382969A1 (en) * 2010-04-30 2011-11-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multicoated Aliskiren formulations
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN103070863A (zh) * 2011-10-25 2013-05-01 河南省健康伟业生物医药研究股份有限公司 阿利吉仑和氨氯地平/左旋氨氯地平的口服固体制剂的制备新工艺
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032954A1 (en) 2001-10-17 2003-04-24 Dr. Reddy's Laboratories Ltd. Stabilized pharmaceutical formulations containing amlodipine maleate
HU226642B1 (en) 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
KR20100137026A (ko) * 2002-05-17 2010-12-29 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
DE10223282B3 (de) 2002-05-24 2004-02-05 Orga Kartensysteme Gmbh Verfahren, Computerprogramm und Computersystem für einen prepaid Telekommunikationsdienst
FR2853904B1 (fr) 2003-04-15 2007-11-16 Air Liquide Procede de production de liquides hydrocarbones mettant en oeuvre un procede fischer-tropsch
RU2426532C2 (ru) * 2004-03-17 2011-08-20 Новартис Аг Применение органических соединений
MY144477A (en) * 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
PL1814527T5 (pl) * 2004-11-05 2021-08-02 Boehringer Ingelheim International Gmbh Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę
WO2006059217A1 (en) 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
US20060116435A1 (en) * 2004-12-01 2006-06-01 Housel Tyler L High strength polyurethane foam
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
PE20120542A1 (es) * 2006-06-27 2012-05-14 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
US8119841B2 (en) * 2006-11-07 2012-02-21 Novartis Ag Crystalline forms of aliskiren hemifumarate

Also Published As

Publication number Publication date
JP2015091830A (ja) 2015-05-14
RU2014140552A (ru) 2015-06-20
TW201016217A (en) 2010-05-01
IL211571A0 (en) 2011-05-31
RU2011115712A (ru) 2012-10-27
WO2010033954A2 (en) 2010-03-25
US20110165240A1 (en) 2011-07-07
BRPI0919350A2 (pt) 2015-12-29
US8613949B2 (en) 2013-12-24
JO3239B1 (ar) 2018-03-08
JP2012503020A (ja) 2012-02-02
CO6351711A2 (es) 2011-12-20
CN102159195A (zh) 2011-08-17
AU2009292908A1 (en) 2010-03-25
CL2011000594A1 (es) 2011-08-05
WO2010033954A3 (en) 2010-10-21
MX2011002988A (es) 2011-04-11
AU2009292908B2 (en) 2012-07-26
CA2736257A1 (en) 2010-03-25
EP2328564A2 (en) 2011-06-08
MA32719B1 (fr) 2011-10-02
AR073384A1 (es) 2010-11-03
ECSP11010999A (es) 2011-06-30
KR20110060942A (ko) 2011-06-08
PE20110293A1 (es) 2011-05-17

Similar Documents

Publication Publication Date Title
PT2205279E (pt) Associação farmacêutica de aliscireno e valsartan
TN2010000135A1 (en) Galenical formulations of organic compounds
SI2046298T1 (sl) Farmacevtska odmerna oblika, ki vsebuje farmacevtsko sprejemljiv solubilizirni sestavek
MX2010004323A (es) Formas de dosificacion oral que comprenden acetato de licarbazepina.
WO2007135193A3 (fr) Forme pharmaceutique orale multimicroparticulaire a liberation prolongee comprenant des moyens anti-mesusage et resistant a l'alcool
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
IL197574A0 (en) Pharmaceutical compositions
NZ592325A (en) Extended release oral acetaminophen/tramadol dosage form
MX343358B (es) Tabletas de acetato de ulipristal.
NZ628513A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
IL195931A0 (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
UA92641C2 (ru) Комбинированная препаративная форма, которая содержит амлодипин и лозартан
IL204528A (en) Pharmaceutical dosage forms for immediate sustained release of metadoxin
CL2012003012A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.
BRPI0925315B8 (pt) composição farmacêutica de dosagem fixa, oral, sólida, estável na forma de um comprimido de monocamada, processo para a preparação da mesma e uso de irbesartan e besilato de amlodipina
WO2008003050A3 (en) Gallium nitrate formulations
MX2007002898A (es) Tableta con liberacion gastrointestinal controlada en sitio y tiempo del ingrediente activo.
WO2010033954A3 (en) Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine
WO2013098268A3 (en) Tablets and dry-coated agents
IL178067A0 (en) Pharmaceutical dosage forms and compositions
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
EP1855647A4 (en) PHARMACEUTICAL ORAL DOSAGE FORM WITH DELAYED RELEASE AND METHOD OF MANUFACTURING THEREOF
PL2008655T3 (pl) Kompozycja farmaceutyczna zawierająca środek przeciwbólowy i witaminy
CL2007002807A1 (es) Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
TN2011000100A1 (en) Galenical formulations of organic compounds